Sanofi's Rimonabant: The Next Drug Safety Victim?
This article was originally published in RPM Report
Executive Summary
Sanofi-Aventis' investigational weight loss drug rimonabant will be the subject of a high-profile advisory committee review smack in the midst of a sensitive political environment for FDA. But even if Sanofi manages to eke out an approval, it will face yet another marketing challenge: the loss of the well-recognized brand name Acomplia.
You may also be interested in...
Novo Nordisk: Riding High on Diabetes
Novo Nordisk is confident that it can continue to generate strong growth from its leading diabetes franchise. Having exited oral anti-diabetics, it's betting on further innovation in insulin and on a strong entry into the GLP-1 analog space.
The Death of Arcoxia: Drug Regulation in a "Whistleblower" Climate
There may not be a worse time to push a new drug through FDA-especially a "me-too" product with a questionable benefit-risk profile. Until Congress releases its grasp on the approval process, FDA isn't taking any chances. Unfortunately for industry, a few drugs are getting caught in the crossfire. Merck seemed unprepared for the new climate with Arcoxia; will other sponsors learn the lesson?
The Death of Arcoxia: Drug Regulation in a "Whistleblower" Climate
There may not be a worse time to push a new drug through FDA-especially a "me-too" product with a questionable benefit-risk profile. Until Congress releases its grasp on the approval process, FDA isn't taking any chances. Unfortunately for industry, a few drugs are getting caught in the crossfire. Merck seemed unprepared for the new climate with Arcoxia; will other sponsors learn the lesson?